ALX Oncology (NASDAQ: ALXO), a clinical-stage biotech company focused on developing cancer therapies, has announced its participation in the upcoming Jefferies 2025 Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, June 5, 2025, at 1:25 PM ET in New York. Investors and interested parties can access the live webcast through ALX Oncology's website investor section, with a replay available for up to 90 days after the event. The conference presentation provides an opportunity for ALX Oncology to showcase its pipeline of novel cancer therapies aimed at treating cancer and extending patient survival.
ALX Oncology (NASDAQ: ALXO), una societ脿 biotecnologica in fase clinica specializzata nello sviluppo di terapie oncologiche, ha annunciato la sua partecipazione alla prossima Jefferies 2025 Global Healthcare Conference. Il management dell'azienda parteciper脿 a una discussione informale prevista per gioved矛 5 giugno 2025 alle 13:25 ET a New York. Investitori e interessati potranno seguire la diretta streaming nella sezione investitori del sito web di ALX Oncology, con la possibilit脿 di rivedere la registrazione fino a 90 giorni dopo l鈥檈vento. La presentazione in conferenza rappresenta un鈥檕ccasione per ALX Oncology di mostrare il proprio portafoglio di nuove terapie oncologiche dedicate al trattamento del cancro e al prolungamento della sopravvivenza dei pazienti.
ALX Oncology (NASDAQ: ALXO), una empresa biotecnol贸gica en etapa cl铆nica enfocada en el desarrollo de terapias contra el c谩ncer, ha anunciado su participaci贸n en la pr贸xima Conferencia Global de Salud Jefferies 2025. La direcci贸n de la empresa participar谩 en una charla informal programada para el jueves 5 de junio de 2025 a la 1:25 PM ET en Nueva York. Inversionistas e interesados podr谩n acceder a la transmisi贸n en vivo a trav茅s de la secci贸n de inversores del sitio web de ALX Oncology, con una repetici贸n disponible hasta 90 d铆as despu茅s del evento. La presentaci贸n en la conferencia ofrece una oportunidad para que ALX Oncology exhiba su cartera de nuevas terapias contra el c谩ncer destinadas a tratar la enfermedad y prolongar la supervivencia de los pacientes.
ALX Oncology (NASDAQ : ALXO), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans le d茅veloppement de th茅rapies contre le cancer, a annonc茅 sa participation 脿 la prochaine conf茅rence mondiale Jefferies 2025 sur la sant茅. La direction de l鈥檈ntreprise participera 脿 une discussion informelle pr茅vue le jeudi 5 juin 2025 脿 13h25 ET 脿 New York. Les investisseurs et les personnes int茅ress茅es pourront acc茅der 脿 la diffusion en direct via la section investisseurs du site web d鈥橝LX Oncology, avec une rediffusion disponible jusqu鈥櫭� 90 jours apr猫s l鈥櫭﹙茅nement. Cette pr茅sentation lors de la conf茅rence offre 脿 ALX Oncology l鈥檕pportunit茅 de mettre en avant son portefeuille de nouvelles th茅rapies anticanc茅reuses visant 脿 traiter le cancer et 脿 prolonger la survie des patients.
ALX Oncology (NASDAQ: ALXO), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf die Entwicklung von Krebstherapien, hat seine Teilnahme an der bevorstehenden Jefferies 2025 Global Healthcare Conference angek眉ndigt. Das Management des Unternehmens wird an einem Fireside-Chat teilnehmen, der f眉r Donnerstag, den 5. Juni 2025, um 13:25 Uhr ET in New York geplant ist. Investoren und Interessierte k枚nnen den Live-Webcast 眉ber den Investor-Bereich der ALX Oncology-Website verfolgen, wobei eine Wiederholung bis zu 90 Tage nach der Veranstaltung verf眉gbar ist. Die Pr盲sentation auf der Konferenz bietet ALX Oncology die Gelegenheit, seine Pipeline neuartiger Krebstherapien vorzustellen, die darauf abzielen, Krebs zu behandeln und das 脺berleben der Patienten zu verl盲ngern.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients鈥� lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows:
Format: Fireside Chat Date: Thursday, June 5, 2025 Time: 1:25 PM ET Location: New York, NY Webcast link: Available聽
The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology鈥檚 website at聽 under the 聽section of the Events and Presentations tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients鈥� lives. ALX Oncology鈥檚 lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology鈥檚 second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at聽聽and on LinkedIn聽.
Investor Relations Contact: Elhan Webb, CFA, IR Consultant
Media Contact: Audra Friis, Sam Brown Healthcare Communications (917) 519-9577
FAQ
When is ALX Oncology (ALXO) presenting at the Jefferies Healthcare Conference 2025?
ALX Oncology will present at the Jefferies Healthcare Conference on Thursday, June 5, 2025, at 1:25 PM ET in New York.
How can I watch ALX Oncology's (ALXO) Jefferies conference presentation?
The presentation can be accessed through the live webcast available in the Investors section of ALX Oncology's website at www.alxoncology.com under Events and Presentations.
How long will ALX Oncology's (ALXO) Jefferies conference presentation be available for replay?
A replay of the webcast will be archived and available for up to 90 days following the fireside chat.
What type of company is ALX Oncology (ALXO)?
ALX Oncology is a clinical-stage biotechnology company that develops novel therapies designed to treat cancer and extend patients' lives.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
